合成肽 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-17 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
== Side effects == The most common side effects reported with naltrexone are gastrointestinal complaints such as diarrhea and abdominal cramping. These adverse effects are analogous to the symptoms of opioid withdrawal, as the μ-opioid receptor blockade will increase gastrointestinal motility. The side effects of naltrexone by incidence are as follows:
== Mechanism of action == Nalfurafine is an orally active, centrally acting, highly potent, selective full agonist of the κ-opioid receptor (KOR) (Ki = 75 pM; EC50 = 25 pM). As touched on above, nalfurafine shows atypical properties as a KOR agonist relative to other drugs. Notably, it does not completely substitute for the prototypical KOR agonist U-50488 in rodents, indicating qualitative differences in the discriminative effects of the two compounds. Moreover, unlike U-50488, it produces neither conditioned place aversion or preference in rodents. The drug is a 4,5-epoxymorphinan derivative, and is structurally unique relative to other KOR agonists. Nalfurafine may be a biased agonist of the KOR or a KOR subtype-selective agonist. Indeed, it has been found to act as a biased agonist of the KOR, preferring activation of β-arrestin signaling in vitro, but paradoxically, β-arrestin appears to be responsible for KOR agonist-induced aversion, and nalfurafine furthermore shows paradoxical effects in vivo that are not consistent with its in vitro profile. As such, more research is needed to clarify the distinct mechanisms and effects of this drug. Nalfurafine has been found in vitro to bind to the μ-opioid receptor and to possess weak partial agonist activity at this site, albeit with much lower affinity relative to the KOR. However, in vivo, nalfurafine has shown no indications of MOR agonism or antagonism in animals or humans, including no evidence of rewarding or reinforcing effects or physical dependence.
In late 2009, the JINR–LLNL collaboration studied the 249Bk + 48Ca reaction in an effort to produce element 117, which would decay to elements 115 and 113 and bolster their claims in a cross-reaction. They were now joined by scientists from Oak Ridge National Laboratory (ORNL) and Vanderbilt University, both in Tennessee, United States, who helped procure the rare and highly radioactive berkelium target necessary to complete the JINR's calcium-48 campaign to synthesise the heaviest elements on the periodic table. Two isotopes of element 117 were synthesised, decaying to element 115 and then element 113:
We knew the world would not be the same. A few people laughed, a few people cried, and most people were silent. I remembered the line from the Hindu scripture the Bhagavad Gita. Vishnu is trying to persuade the prince that he should do his duty and to impress him takes on his multiarmed form and says, "Now, I am become Death, the destroyer of worlds." I suppose we all thought that one way or another.
Sources: en.wikipedia.org
Plant hormones affect seed germination and dormancy by acting on different parts of the seed. Embryo dormancy is characterized by a high ABA:GA ratio, whereas the seed has high abscisic acid sensitivity and low GA sensitivity. In order to release the seed from this type of dormancy and initiate seed germination, an alteration in hormone biosynthesis and degradation toward a low ABA/GA ratio, along with a decrease in ABA sensitivity and an increase in GA sensitivity, must occur. ABA controls embryo dormancy, and GA embryo germination. Seed coat dormancy involves the mechanical restriction of the seed coat. This, along with a low embryo growth potential, effectively produces seed dormancy. GA releases this dormancy by increasing the embryo growth potential, and/or weakening the seed coat so the radical of the seedling can break through the seed coat. Different types of seed coats can be made up of living or dead cells, and both types can be influenced by hormones; those composed of living cells are acted upon after seed formation, whereas the seed coats composed of dead cells can be influenced by hormones during the formation of the seed coat. ABA affects testa or seed coat growth characteristics, including thickness, and effects the GA-mediated embryo growth potential. These conditions and effects occur during the formation of the seed, often in response to environmental conditions. Hormones also mediate endosperm dormancy: Endosperm in most seeds is composed of living tissue that can actively respond to hormones generated by the embryo.
Lipases are a type of enzyme that break down fats. More specifically, lipases use water (as hydrolases) to remove fatty acids from fat molecules, especially triglycerides or its derivatives. In humans and other animals, lipases have a variety of roles in the body, from helping digest dietary fats like pancreatic lipase, to synthesizing fat-based hormones like diglyceride lipases. What counts as a lipase is not consistently defined across sources, and some only consider enzymes to be lipases if they are activated by oil-water interfaces. Many specific lipases can also catalyze other reactions. For example, carboxyl ester lipase is able to remove fatty acids that are attached to cholesterol, while endothelial lipase can remove fatty acids from phospholipids (a major component of cell membranes).
=== Pharmacokinetics === Desloratadine is well absorbed from the gut and reaches highest blood plasma concentrations after about three hours. In the bloodstream, 83 to 87% of the substance are bound to plasma proteins. Desloratadine is metabolized to 3-hydroxydesloratadine in a three-step sequence in normal metabolizers. First, N-glucuronidation of desloratadine by UGT2B10; then, 3-hydroxylation of desloratadine N-glucuronide by CYP2C8; and finally, a non-enzymatic deconjugation of 3-hydroxydesloratadine N-glucuronide. Both desloratadine and 3-hydroxydesloratadine are eliminated via urine and feces with a half-life of 27 hours in normal metabolizers.
Degradation of Oligopeptide Sequences in N-(2-Hydroxypropyl)methacrylamide Copolymers by Bovine Spleen Cathepsin B". Die Makromolekulare Chemie 184, 2009–2020 (1983) K. Ulbrich, J. Strohalm, J. Kopeček, "Polymers Containing Enzymatically Degradable Bonds. 6. Hydrophilic Gels Cleavable by Chymotrypsin". Biomaterials 3, 150–154 (1982) J. Kopeček, P. Rejmanová, V. Chytrý, "Polymers Containing Enzymatically Degradable Bonds. 1. Chymotrypsin Catalyzed Hydrolysis of p-Nitroanilides of Phenylalanine and Tyrosine Attached to Side-Chains of Copolymers of N-(2-Hydroxypropyl)methacrylamide". Die Makromolekulare Chemie 182, 799–809 (1981) J. Kopeček, "Soluble Biomedical Polymers". Polymers in Medicine (Wroclaw) 7, 191–221 (1977) Z. Voldřich, Z. Tománek, J. Vacík, J. Kopeček, "Long-Term Experience with the Poly(Glycol Monomethacrylate) Gel in Plastic Operations of the Nose". Journal of Biomedical Materials Research 9, 675–685 (1975) J. Kopeček, H. Bažilová, Poly[N-(2-Hydroxypropyl)methacrylamide]. 1. "Radical Polymerization and Copolymerization". European Polymer Journal J. 9, 7–14 (1973) J. Kopeček, J. Vacík, D. Lím, "Permeability of Membranes Containing Ionogenic Groups". Journal of Polymer Science A-1, 9, 2801–2815 (1971) L. Šprincl, J. Kopeček, D. Lím, "Effect of Porosity of Heterogeneous Poly(Glycol Monomethacrylate) Gels on the Healing-in of Test Implants". Journal of Biomedical Materials Research 5, 447–458 (1971) J. Kopeček, J. Jokl, D. Lím, "Mechanism of Three-Dimensional Polymerization of Glycol Methacrylates" (in German). Journal of Polymer Science C 16, 3877–3889 (1968)
linking to primary rather than secondary sources and prioritizing stable sites avoiding links that point to resources on researchers' personal pages using clean URLs or otherwise employing URL normalization or URL canonicalization using permalinks and persistent identifiers such as ARKs, DOIs, Handle System references, PURLs, or content addressing avoiding linking to documents other than web pages avoiding deep linking linking to web archives such as the Internet Archive, WebCite, archive.today, Perma.cc, Amber, or Arweave Strategies pertaining to the protection of existing links include:
Sources: en.wikipedia.org
It has hitherto been necessary to postulate some special arbitrary "instability" of the nucleus, but in the following note, it is pointed out that disintegration is a natural consequence of the laws of quantum mechanics without any special hypothesis... Much has been written of the explosive violence with which the α-particle is hurled from its place in the nucleus. But from the process pictured above, one would rather say that the α-particle almost slips away unnoticed. The theory supposes that the alpha particle can be considered an independent particle within a nucleus, that is in constant motion but held within the nucleus by strong interaction. At each collision with the repulsive potential barrier of the electromagnetic force, there is a small non-zero probability that it will tunnel its way out. An alpha particle with a speed of 1.5×107 m/s within a nuclear diameter of approximately 10−14 m will collide with the barrier more than 1021 times per second. However, if the probability of escape at each collision is very small, the half-life of the radioisotope will be very long, since it is the time required for the total probability of escape to reach 50%. As an extreme example, the half-life of the isotope bismuth-209 is 2.01×1019 years. The isotopes in beta-decay stable isobars that are also stable with regards to double beta decay with mass number A = 5, A = 8, 143 ≤ A ≤ 155, 160 ≤ A ≤ 162, and A ≥ 165 are theorized to undergo alpha decay. All other mass numbers (isobars) have exactly one theoretically stable nuclide.
=== 1968-71 === Lundy played in only five games in 1968 and four in 1969 to end his career. In 1968, Gregg Schumacher started nine games in Lundy's place, with 8.5 sacks. Schumacher suffered a knee injury during training camp the following year, and never played again in the NFL. Third-year player Diron Talbert replaced Schumacher and became the starting right defensive end in 1969. Brown suffered a broken hand in 1969, his final NFL season, and split time at tackle with second-year player Coy Bacon. In 1970, Talbert would take over Brown's spot at right tackle, and Bacon would become the starting right defensive end. The greater publicity garnered by the NFL leads many to assume incorrectly the Rams were the original Fearsome Foursome, before the Chargers. The Rams' Fearsome Foursome's first three years came under head coach Harland Svare, who had played linebacker behind the Giants' Fearsome Foursome during his playing days. The Rams best record under Svare was 5–7–2 during that time, and the team had not been over .500 since 1959. Starting in 1966, the Rams became playoff contenders under coach George Allen, who had a 49–17–4 record from 1966 to 1970 with the Rams. They had a league best record of 11–1–2 in 1967, and reached the playoffs twice during Allen's tenure. From 1963-70, the line averaged 44 quarterback sacks per year, and led the NFL in rushing defense three times from 1964 to 1968, showing excellence in both pass and run defense. The line was ultimately broken up after 1971, George Allen having become coach of the Washington Redskins in 1971.
=== Toluene disproportionation === Toluene disproportionation (TDP) is the conversion of toluene to benzene and xylene. Given that demand for para-xylene (p-xylene) substantially exceeds demand for other xylene isomers, a refinement of the TDP process called Selective TDP (STDP) may be used. In this process, the xylene stream exiting the TDP unit is approximately 90% p-xylene. In some systems, even the benzene-to-xylenes ratio is modified to favor xylenes.
N-Acetylaspartylglutamic acid (N-acetylaspartylglutamate or NAAG) is a peptide neurotransmitter and the third-most-prevalent neurotransmitter in the mammalian nervous system. NAAG consists of N-acetylaspartic acid (NAA) and glutamic acid coupled via a peptide bond. NAAG was discovered as a nervous system-specific peptide in 1965 by Curatolo and colleagues but initially disregarded as a neurotransmitter and not extensively studied. However it meets the criteria for a neurotransmitter, including being concentrated in neurons, packed in synaptic vesicles, released in a calcium-dependent manner, and hydrolyzed in the synaptic space by enzymatic activity. NAAG activates a specific receptor, the metabotropic glutamate receptor type 3. It is synthesized enzymatically from its two precursors and catabolized by NAAG peptidases in the synapse. The inhibition of the latter enzymes has potentially important therapeutic effects in animal models of several neurologic conditions and disorders. Under the INN spaglumic acid, NAAG is used as an antiallergic medication in eye drops and nasal preparations.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。